Drug profile · INN
olezarsen sodium
TRYNGOLZA (AUTOINJECTOR)
olezarsen sodium (TRYNGOLZA (AUTOINJECTOR)) is an FDA-listed pharmaceutical active ingredient. Associated with IONIS PHARMACEUTICALS INC. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — olezarsen sodium
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 20
- Programs
- 5
- Data quality
- 0.89
Quick answer
olezarsen sodium (TRYNGOLZA (AUTOINJECTOR)) is an FDA-listed pharmaceutical active ingredient. Associated with IONIS PHARMACEUTICALS INC. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12410430
Modulating apolipoprotein (A) expression
granted -
US 12409188
Modulators of HSD17B13 expression
granted -
US 12364753
CD8 binding agents
granted -
US 12350285
Compounds and methods for reducing ATXN3 expression
granted -
US 12351633
PD-1 and PD-L1 binding agents
granted -
US 12343357
Compositions and methods for modulating MECP2 expression
granted -
US 12297431
Modulation of huntingtin expression
granted -
US 12291709
Compositions and methods for modulating apolipoprotein (a) expression
granted -
US 12281305
Compounds and methods for reducing prion expression
granted -
US 12241067
Compounds and methods for reducing LRRK2 expression
granted -
US 12227746
Compounds and methods for modulating SCN2A
granted -
US 12188020
Methods for reducing Ataxin-2 expression
granted -
US 12180479
Compounds and methods for modulating ATXN1
granted -
US 12115225
GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
granted -
US 12110491
Selective reduction of allelic variants
granted -
US 12042510
Modulators of IRF4 expression
granted -
US 12043831
Modulation of alpha synuclein expression
granted -
US 12030910
Compounds and methods for the modulation of proteins
granted -
US 12018261
Compounds and methods for modulating factor XII
granted -
US 11959080
Methods and compositions for inhibiting PMP22 expression
granted
Frequently asked questions
What is olezarsen sodium?
olezarsen sodium (TRYNGOLZA (AUTOINJECTOR)) is an FDA-listed pharmaceutical active ingredient. Associated with IONIS PHARMACEUTICALS INC. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for olezarsen sodium?
TRYNGOLZA (AUTOINJECTOR) is a marketed brand name for olezarsen sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olezarsen sodium?
olezarsen sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.